| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 44.51% | Barclays | $590 → $592 | Maintains | Overweight |
| 10/30/2023 | 12.29% | Stifel | $500 → $460 | Maintains | Hold |
| 09/15/2023 | 22.06% | Stifel | $525 → $500 | Maintains | Hold |
| 08/03/2023 | 46.47% | Morgan Stanley | $590 → $600 | Maintains | Overweight |
| 08/02/2023 | 46.47% | JP Morgan | $550 → $600 | Maintains | Overweight |
| 08/02/2023 | 46.47% | Atlantic Equities | → $600 | Downgrades | Overweight → Neutral |
| 06/07/2023 | 46.47% | Atlantic Equities | → $600 | Reiterates | Overweight → Overweight |
| 05/03/2023 | 46.47% | Atlantic Equities | → $600 | Reiterates | → Overweight |
| 03/23/2023 | 44.03% | Morgan Stanley | $543 → $590 | Maintains | Overweight |
| 02/08/2023 | 44.03% | Barclays | $582 → $590 | Maintains | Overweight |
| 02/07/2023 | 34.26% | JP Morgan | $525 → $550 | Maintains | Overweight |
| 02/07/2023 | 46.47% | Atlantic Equities | $470 → $600 | Maintains | Overweight |
| 01/25/2023 | 29.38% | Goldman Sachs | $465 → $530 | Maintains | Buy |
| 11/15/2022 | 32.55% | Morgan Stanley | $573 → $543 | Maintains | Overweight |
| 11/02/2022 | 14.73% | Atlantic Equities | $490 → $470 | Maintains | Overweight |
| 10/17/2022 | 9.85% | JP Morgan | $525 → $450 | Maintains | Overweight |
| 08/05/2022 | 42.07% | Barclays | $700 → $582 | Maintains | Overweight |
| 08/04/2022 | 39.88% | Morgan Stanley | $603 → $573 | Maintains | Overweight |
| 08/03/2022 | 19.61% | Atlantic Equities | $500 → $490 | Maintains | Overweight |
| 07/26/2022 | 2.53% | Piper Sandler | $440 → $420 | Maintains | Overweight |
| 07/25/2022 | 1.31% | Stifel | $500 → $415 | Downgrades | Buy → Hold |
| 07/21/2022 | 6.19% | Goldman Sachs | $530 → $435 | Upgrades | Neutral → Buy |
| 07/12/2022 | 7.41% | Piper Sandler | → $440 | Initiates Coverage On | → Overweight |
| 06/24/2022 | 22.06% | Stifel | $575 → $500 | Maintains | Buy |
| 05/19/2022 | 29.38% | Goldman Sachs | $615 → $530 | Maintains | Neutral |
| 05/05/2022 | 47.2% | Morgan Stanley | $732 → $603 | Maintains | Overweight |
| 05/05/2022 | 14.73% | B of A Securities | $550 → $470 | Downgrades | Buy → Neutral |
| 02/08/2022 | 58.67% | Atlantic Equities | → $650 | Initiates Coverage On | → Overweight |
| 11/18/2021 | 78.69% | Morgan Stanley | → $732 | Initiates Coverage On | → Overweight |
| 08/13/2021 | 87.97% | Credit Suisse | $735 → $770 | Maintains | Outperform |
| 08/03/2021 | 48.91% | Goldman Sachs | $550 → $610 | Maintains | Neutral |
| 08/02/2021 | 83.08% | Barclays | $616 → $750 | Maintains | Overweight |
| 07/12/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 02/17/2021 | 46.47% | Barclays | → $600 | Initiates Coverage On | → Overweight |
| 01/29/2021 | 39.14% | JP Morgan | → $570 | Initiates Coverage On | → Overweight |
| 08/17/2020 | 3.01% | Credit Suisse | $415 → $422 | Maintains | Outperform |
| 07/30/2020 | -8.46% | Stifel | $280 → $375 | Maintains | Buy |
| 07/20/2020 | -4.8% | B of A Securities | $300 → $390 | Maintains | Buy |
| 05/01/2020 | -31.65% | Stifel | $266 → $280 | Maintains | Buy |
| 09/09/2019 | -32.38% | Goldman Sachs | → $277 | Initiates Coverage On | → Neutral |
| 08/16/2019 | -28.48% | Credit Suisse | $282 → $293 | Maintains | Outperform |
| 07/22/2019 | -27.99% | Stifel | $255 → $295 | Maintains | Buy |
| 05/23/2019 | -32.63% | Guggenheim | → $276 | Initiates Coverage On | → Buy |
| 05/02/2019 | -36.53% | Canaccord Genuity | $255 → $260 | Maintains | Buy |
| 11/05/2018 | -38.97% | Canaccord Genuity | $270 → $250 | Maintains | Buy |
| 11/02/2018 | -42.63% | B of A Securities | $275 → $235 | Maintains | Buy |
What is the target price for IDEXX Laboratories (IDXX)?
The latest price target for IDEXX Laboratories (NASDAQ: IDXX) was reported by Barclays on November 2, 2023. The analyst firm set a price target for $592.00 expecting IDXX to rise to within 12 months (a possible 44.51% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEXX Laboratories (IDXX)?
The latest analyst rating for IDEXX Laboratories (NASDAQ: IDXX) was provided by Barclays, and IDEXX Laboratories maintained their overweight rating.
When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating IDEXX Laboratories (IDXX) correct?
While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $590.00 to $592.00. The current price IDEXX Laboratories (IDXX) is trading at is $409.65, which is out of the analyst's predicted range.